APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

OTC Anti-Infective Medications

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global OTC Anti-Infective Medications Market Analysis and Forecast 2026-2032

Report ID 17402097022 January 2026196 pages

Choose your research edition.

Industry ResearchOTC Anti-Infective Medications Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal OTC Anti-Infective Medications Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal OTC Anti-Infective Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OTC Anti-Infective Medications Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal OTC Anti-Infective Medications Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global OTC Anti-Infective Medications market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for OTC Anti-Infective Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for OTC Anti-Infective Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for OTC Anti-Infective Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for OTC Anti-Infective Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of OTC Anti-Infective Medications include Abbott, Sanofi, Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, Optimer Pharmaceuticals and Novabay Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for OTC Anti-Infective Medications, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of OTC Anti-Infective Medications, also provides the revenue of main regions and countries. Of the upcoming market potential for OTC Anti-Infective Medications, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the OTC Anti-Infective Medications revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global OTC Anti-Infective Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for OTC Anti-Infective Medications revenue, projected growth trends, production technology, application and end-user industry.

OTC Anti-Infective Medications Segment by Company

Abbott

Sanofi

Novartis

Merck

Roche

Pfizer

GlaxoSmithKline

Optimer Pharmaceuticals

Novabay Pharmaceuticals

NanoViricides

MerLion Pharma

Bristol-Myers Squibb

Basilea Pharmaceutica

OTC Anti-Infective Medications Segment by Type

Antiseptic

Antiparasitics

Antifungals

OTC Anti-Infective Medications Segment by Application

E-Commerce

Drug Stores

Hospital Pharmacies

OTC Anti-Infective Medications Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of OTC Anti-Infective Medications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of OTC Anti-Infective Medications company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, OTC Anti-Infective Medications revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global OTC Anti-Infective Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antiseptic Major Player Table 3. Antiparasitics Major Player Table 4. Antifungals Major Player Table 5. Global OTC Anti-Infective Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. E-Commerce Major Player Table 7. Drug Stores Major Player Table 8. Hospital Pharmacies Major Player Table 9. OTC Anti-Infective Medications Industry Trends Table 10. OTC Anti-Infective Medications Industry Drivers Table 11. OTC Anti-Infective Medications Industry Opportunities and Challenges Table 12. OTC Anti-Infective Medications Industry Restraints Table 13. Global OTC Anti-Infective Medications Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global OTC Anti-Infective Medications Market Size by Region (2021-2026) & (US$ Million) Table 15. Global OTC Anti-Infective Medications Market Share by Region (2021-2026) Table 16. Global OTC Anti-Infective Medications Market Size by Region (2027-2032) & (US$ Million) Table 17. Global OTC Anti-Infective Medications Market Share by Region (2027-2032) Table 18. Global OTC Anti-Infective Medications Revenue by Players (US$ Million) & (2021-2026) Table 19. Global OTC Anti-Infective Medications Revenue Market Share by Players (2021-2026) Table 20. Global OTC Anti-Infective Medications Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global OTC Anti-Infective Medications Key Players Headquarters & Area Served Table 22. Global OTC Anti-Infective Medications Players, Product Type & Application Table 23. Global OTC Anti-Infective Medications Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global OTC Anti-Infective Medications by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global OTC Anti-Infective Medications Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 28. Global OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 29. Global OTC Anti-Infective Medications Revenue Market Share by Type (2021-2026) Table 30. Global OTC Anti-Infective Medications Revenue Market Share by Type (2027-2032) Table 31. Global OTC Anti-Infective Medications Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 33. Global OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 34. Global OTC Anti-Infective Medications Revenue Market Share by Application (2021-2026) Table 35. Global OTC Anti-Infective Medications Revenue Market Share by Application (2027-2032) Table 36. Abbott Company Information Table 37. Abbott Business Overview Table 38. Abbott OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Abbott OTC Anti-Infective Medications Product Portfolio Table 40. Abbott Recent Development Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sanofi OTC Anti-Infective Medications Product Portfolio Table 45. Sanofi Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis OTC Anti-Infective Medications Product Portfolio Table 50. Novartis Recent Development Table 51. Merck Company Information Table 52. Merck Business Overview Table 53. Merck OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Merck OTC Anti-Infective Medications Product Portfolio Table 55. Merck Recent Development Table 56. Roche Company Information Table 57. Roche Business Overview Table 58. Roche OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Roche OTC Anti-Infective Medications Product Portfolio Table 60. Roche Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Pfizer OTC Anti-Infective Medications Product Portfolio Table 65. Pfizer Recent Development Table 66. GlaxoSmithKline Company Information Table 67. GlaxoSmithKline Business Overview Table 68. GlaxoSmithKline OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio Table 70. GlaxoSmithKline Recent Development Table 71. Optimer Pharmaceuticals Company Information Table 72. Optimer Pharmaceuticals Business Overview Table 73. Optimer Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio Table 75. Optimer Pharmaceuticals Recent Development Table 76. Novabay Pharmaceuticals Company Information Table 77. Novabay Pharmaceuticals Business Overview Table 78. Novabay Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio Table 80. Novabay Pharmaceuticals Recent Development Table 81. NanoViricides Company Information Table 82. NanoViricides Business Overview Table 83. NanoViricides OTC Anti-Infective Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. NanoViricides OTC Anti-Infective Medications Product Portfolio Table 85. NanoViricides Recent Development Table 86. MerLion Pharma Company Information Table 87. MerLion Pharma Business Overview Table 88. MerLion Pharma OTC Anti-Infective Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. MerLion Pharma OTC Anti-Infective Medications Product Portfolio Table 90. MerLion Pharma Recent Development Table 91. Bristol-Myers Squibb Company Information Table 92. Bristol-Myers Squibb Business Overview Table 93. Bristol-Myers Squibb OTC Anti-Infective Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio Table 95. Bristol-Myers Squibb Recent Development Table 96. Basilea Pharmaceutica Company Information Table 97. Basilea Pharmaceutica Business Overview Table 98. Basilea Pharmaceutica OTC Anti-Infective Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio Table 100. Basilea Pharmaceutica Recent Development Table 101. North America OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 102. North America OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 103. North America OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 104. North America OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 105. North America OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America OTC Anti-Infective Medications Revenue by Country (2021-2026) & (US$ Million) Table 107. North America OTC Anti-Infective Medications Revenue by Country (US$ Million) & (2027-2032) Table 108. Europe OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 109. Europe OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 110. Europe OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe OTC Anti-Infective Medications Revenue by Country (2021-2026) & (US$ Million) Table 114. Europe OTC Anti-Infective Medications Revenue by Country (US$ Million) & (2027-2032) Table 115. China OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 116. China OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 117. China OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 118. China OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 120. Asia OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 121. Asia OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 122. Asia OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia OTC Anti-Infective Medications Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia OTC Anti-Infective Medications Revenue by Region (US$ Million) & (2021-2026) Table 125. Asia OTC Anti-Infective Medications Revenue by Region (US$ Million) & (2027-2032) Table 126. SAMEA OTC Anti-Infective Medications Revenue by Type (2021-2026) & (US$ Million) Table 127. SAMEA OTC Anti-Infective Medications Revenue by Type (2027-2032) & (US$ Million) Table 128. SAMEA OTC Anti-Infective Medications Revenue by Application (2021-2026) & (US$ Million) Table 129. SAMEA OTC Anti-Infective Medications Revenue by Application (2027-2032) & (US$ Million) Table 130. SAMEA OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. SAMEA OTC Anti-Infective Medications Revenue by Country (2021-2026) & (US$ Million) Table 132. SAMEA OTC Anti-Infective Medications Revenue by Country (US$ Million) & (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. OTC Anti-Infective Medications Image Figure 2. Global OTC Anti-Infective Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OTC Anti-Infective Medications Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antiseptic Image Figure 5. Antiparasitics Image Figure 6. Antifungals Image Figure 7. Global OTC Anti-Infective Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global OTC Anti-Infective Medications Market Size Share 2021 VS 2025 VS 2032 Figure 9. E-Commerce Image Figure 10. Drug Stores Image Figure 11. Hospital Pharmacies Image Figure 12. Global OTC Anti-Infective Medications Market Size (US$ Million) & (2021-2032) Figure 13. Global OTC Anti-Infective Medications Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global OTC Anti-Infective Medications Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global OTC Anti-Infective Medications Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global OTC Anti-Infective Medications Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global OTC Anti-Infective Medications Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global OTC Anti-Infective Medications Revenue Market Share by Type (2021-2032) Figure 20. Global OTC Anti-Infective Medications Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global OTC Anti-Infective Medications Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global OTC Anti-Infective Medications Revenue Market Share by Application (2021-2032) Figure 23. North America OTC Anti-Infective Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America OTC Anti-Infective Medications Revenue Share by Type (2021-2032) Figure 25. North America OTC Anti-Infective Medications Revenue Share by Application (2021-2032) Figure 26. North America OTC Anti-Infective Medications Revenue Share by Country (2021-2032) Figure 27. United States OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe OTC Anti-Infective Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe OTC Anti-Infective Medications Revenue Share by Type (2021-2032) Figure 32. Europe OTC Anti-Infective Medications Revenue Share by Application (2021-2032) Figure 33. Europe OTC Anti-Infective Medications Revenue Share by Country (2021-2032) Figure 34. Germany OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China OTC Anti-Infective Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China OTC Anti-Infective Medications Revenue Share by Type (2021-2032) Figure 44. China OTC Anti-Infective Medications Revenue Share by Application (2021-2032) Figure 45. Asia OTC Anti-Infective Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia OTC Anti-Infective Medications Revenue Share by Type (2021-2032) Figure 47. Asia OTC Anti-Infective Medications Revenue Share by Application (2021-2032) Figure 48. Asia OTC Anti-Infective Medications Revenue Share by Region (2021-2032) Figure 49. Japan OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA OTC Anti-Infective Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA OTC Anti-Infective Medications Revenue Share by Type (2021-2032) Figure 57. SAMEA OTC Anti-Infective Medications Revenue Share by Application (2021-2032) Figure 58. SAMEA OTC Anti-Infective Medications Revenue Share by Country (2021-2032) Figure 59. Brazil OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt OTC Anti-Infective Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Antiseptic
  • Antiparasitics
  • Antifungals
Applications
  • E-Commerce
  • Drug Stores
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Optimer Pharmaceuticals
  • Novabay Pharmaceuticals
  • NanoViricides
  • MerLion Pharma
  • Bristol-Myers Squibb
  • Basilea Pharmaceutica

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 OTC Anti-Infective Medications Market by Type
  3. 1.2.1 Global OTC Anti-Infective Medications Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antiseptic
  5. 1.2.3 Antiparasitics
  6. 1.2.4 Antifungals
  7. 1.3 OTC Anti-Infective Medications Market by Application
  8. 1.3.1 Global OTC Anti-Infective Medications Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 E-Commerce
  10. 1.3.3 Drug Stores
  11. 1.3.4 Hospital Pharmacies
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 OTC Anti-Infective Medications Market Dynamics
  1. 2.1 OTC Anti-Infective Medications Industry Trends
  2. 2.2 OTC Anti-Infective Medications Industry Drivers
  3. 2.3 OTC Anti-Infective Medications Industry Opportunities and Challenges
  4. 2.4 OTC Anti-Infective Medications Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global OTC Anti-Infective Medications Market Perspective (2021-2032)
  2. 3.2 Global OTC Anti-Infective Medications Growth Trends by Region
  3. 3.2.1 Global OTC Anti-Infective Medications Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global OTC Anti-Infective Medications Market Size by Region (2021-2026)
  5. 3.2.3 Global OTC Anti-Infective Medications Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global OTC Anti-Infective Medications Revenue by Players
  2. 4.1.1 Global OTC Anti-Infective Medications Revenue by Players (2021-2026)
  3. 4.1.2 Global OTC Anti-Infective Medications Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global OTC Anti-Infective Medications Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global OTC Anti-Infective Medications Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global OTC Anti-Infective Medications Key Players Headquarters & Area Served
  7. 4.4 Global OTC Anti-Infective Medications Players, Product Type & Application
  8. 4.5 Global OTC Anti-Infective Medications Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global OTC Anti-Infective Medications Market CR5 and HHI
  11. 4.6.3 2025 OTC Anti-Infective Medications Tier 1, Tier 2, and Tier 3
5 OTC Anti-Infective Medications Market Size by Type
  1. 5.1 Global OTC Anti-Infective Medications Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 5.3 Global OTC Anti-Infective Medications Revenue Market Share by Type (2021-2032)
6 OTC Anti-Infective Medications Market Size by Application
  1. 6.1 Global OTC Anti-Infective Medications Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global OTC Anti-Infective Medications Revenue by Application (2021-2032)
  3. 6.3 Global OTC Anti-Infective Medications Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott OTC Anti-Infective Medications Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi OTC Anti-Infective Medications Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis OTC Anti-Infective Medications Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck OTC Anti-Infective Medications Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche OTC Anti-Infective Medications Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer OTC Anti-Infective Medications Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 GlaxoSmithKline
  38. 7.7.1 GlaxoSmithKline Company Information
  39. 7.7.2 GlaxoSmithKline Business Overview
  40. 7.7.3 GlaxoSmithKline OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio
  42. 7.7.5 GlaxoSmithKline Recent Developments
  43. 7.8 Optimer Pharmaceuticals
  44. 7.8.1 Optimer Pharmaceuticals Company Information
  45. 7.8.2 Optimer Pharmaceuticals Business Overview
  46. 7.8.3 Optimer Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
  48. 7.8.5 Optimer Pharmaceuticals Recent Developments
  49. 7.9 Novabay Pharmaceuticals
  50. 7.9.1 Novabay Pharmaceuticals Company Information
  51. 7.9.2 Novabay Pharmaceuticals Business Overview
  52. 7.9.3 Novabay Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
  54. 7.9.5 Novabay Pharmaceuticals Recent Developments
  55. 7.10 NanoViricides
  56. 7.10.1 NanoViricides Company Information
  57. 7.10.2 NanoViricides Business Overview
  58. 7.10.3 NanoViricides OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  59. 7.10.4 NanoViricides OTC Anti-Infective Medications Product Portfolio
  60. 7.10.5 NanoViricides Recent Developments
  61. 7.11 MerLion Pharma
  62. 7.11.1 MerLion Pharma Company Information
  63. 7.11.2 MerLion Pharma Business Overview
  64. 7.11.3 MerLion Pharma OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  65. 7.11.4 MerLion Pharma OTC Anti-Infective Medications Product Portfolio
  66. 7.11.5 MerLion Pharma Recent Developments
  67. 7.12 Bristol-Myers Squibb
  68. 7.12.1 Bristol-Myers Squibb Company Information
  69. 7.12.2 Bristol-Myers Squibb Business Overview
  70. 7.12.3 Bristol-Myers Squibb OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio
  72. 7.12.5 Bristol-Myers Squibb Recent Developments
  73. 7.13 Basilea Pharmaceutica
  74. 7.13.1 Basilea Pharmaceutica Company Information
  75. 7.13.2 Basilea Pharmaceutica Business Overview
  76. 7.13.3 Basilea Pharmaceutica OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio
  78. 7.13.5 Basilea Pharmaceutica Recent Developments
8 North America
  1. 8.1 North America OTC Anti-Infective Medications Revenue (2021-2032)
  2. 8.2 North America OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 8.2.1 North America OTC Anti-Infective Medications Revenue by Type (2021-2026)
  4. 8.2.2 North America OTC Anti-Infective Medications Revenue by Type (2027-2032)
  5. 8.3 North America OTC Anti-Infective Medications Revenue Share by Type (2021-2032)
  6. 8.4 North America OTC Anti-Infective Medications Revenue by Application (2021-2032)
  7. 8.4.1 North America OTC Anti-Infective Medications Revenue by Application (2021-2026)
  8. 8.4.2 North America OTC Anti-Infective Medications Revenue by Application (2027-2032)
  9. 8.5 North America OTC Anti-Infective Medications Revenue Share by Application (2021-2032)
  10. 8.6 North America OTC Anti-Infective Medications Revenue by Country
  11. 8.6.1 North America OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America OTC Anti-Infective Medications Revenue by Country (2021-2026)
  13. 8.6.3 North America OTC Anti-Infective Medications Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe OTC Anti-Infective Medications Revenue (2021-2032)
  2. 9.2 Europe OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 9.2.1 Europe OTC Anti-Infective Medications Revenue by Type (2021-2026)
  4. 9.2.2 Europe OTC Anti-Infective Medications Revenue by Type (2027-2032)
  5. 9.3 Europe OTC Anti-Infective Medications Revenue Share by Type (2021-2032)
  6. 9.4 Europe OTC Anti-Infective Medications Revenue by Application (2021-2032)
  7. 9.4.1 Europe OTC Anti-Infective Medications Revenue by Application (2021-2026)
  8. 9.4.2 Europe OTC Anti-Infective Medications Revenue by Application (2027-2032)
  9. 9.5 Europe OTC Anti-Infective Medications Revenue Share by Application (2021-2032)
  10. 9.6 Europe OTC Anti-Infective Medications Revenue by Country
  11. 9.6.1 Europe OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe OTC Anti-Infective Medications Revenue by Country (2021-2026)
  13. 9.6.3 Europe OTC Anti-Infective Medications Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China OTC Anti-Infective Medications Revenue (2021-2032)
  2. 10.2 China OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 10.2.1 China OTC Anti-Infective Medications Revenue by Type (2021-2026)
  4. 10.2.2 China OTC Anti-Infective Medications Revenue by Type (2027-2032)
  5. 10.3 China OTC Anti-Infective Medications Revenue Share by Type (2021-2032)
  6. 10.4 China OTC Anti-Infective Medications Revenue by Application (2021-2032)
  7. 10.4.1 China OTC Anti-Infective Medications Revenue by Application (2021-2026)
  8. 10.4.2 China OTC Anti-Infective Medications Revenue by Application (2027-2032)
  9. 10.5 China OTC Anti-Infective Medications Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia OTC Anti-Infective Medications Revenue (2021-2032)
  2. 11.2 Asia OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 11.2.1 Asia OTC Anti-Infective Medications Revenue by Type (2021-2026)
  4. 11.2.2 Asia OTC Anti-Infective Medications Revenue by Type (2027-2032)
  5. 11.3 Asia OTC Anti-Infective Medications Revenue Share by Type (2021-2032)
  6. 11.4 Asia OTC Anti-Infective Medications Revenue by Application (2021-2032)
  7. 11.4.1 Asia OTC Anti-Infective Medications Revenue by Application (2021-2026)
  8. 11.4.2 Asia OTC Anti-Infective Medications Revenue by Application (2027-2032)
  9. 11.5 Asia OTC Anti-Infective Medications Revenue Share by Application (2021-2032)
  10. 11.6 Asia OTC Anti-Infective Medications Revenue by Country
  11. 11.6.1 Asia OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia OTC Anti-Infective Medications Revenue by Country (2021-2026)
  13. 11.6.3 Asia OTC Anti-Infective Medications Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA OTC Anti-Infective Medications Revenue (2021-2032)
  2. 12.2 SAMEA OTC Anti-Infective Medications Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA OTC Anti-Infective Medications Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA OTC Anti-Infective Medications Revenue by Type (2027-2032)
  5. 12.3 SAMEA OTC Anti-Infective Medications Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA OTC Anti-Infective Medications Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA OTC Anti-Infective Medications Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA OTC Anti-Infective Medications Revenue by Application (2027-2032)
  9. 12.5 SAMEA OTC Anti-Infective Medications Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA OTC Anti-Infective Medications Revenue by Country
  11. 12.6.1 SAMEA OTC Anti-Infective Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA OTC Anti-Infective Medications Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA OTC Anti-Infective Medications Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst